

Erik Dubberke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8990351/publications.pdf>

Version: 2024-02-01

125
papers

7,986
citations

81434

41
h-index

56606

87
g-index

126
all docs

126
docs citations

126
times ranked

7602
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized controlled trial of <i>Lactobacillus rhamnosus</i> GG on antimicrobial-resistant organism colonization. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 167-173.	1.0	6
2	Multi-omics investigation of <i>Clostridioides difficile</i> -colonized patients reveals pathogen and commensal correlates of <i>C. difficile</i> pathogenesis. <i>ELife</i> , 2022, 11, .	2.8	16
3	American Society for Transplantation and Cellular Therapy Series: "Management of <i>Clostridioides difficile</i> Infection in Hematopoietic Cell Transplant Recipients. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 225-232.	0.6	9
4	Durable reduction of <i>Clostridioides difficile</i> infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial. <i>BMC Infectious Diseases</i> , 2022, 22, 245.	1.3	38
5	Kidney Transplantation from COVID-19 Deceased Donors: New Hope on the Horizon. <i>American Journal of Nephrology</i> , 2022, , 1-2.	1.4	0
6	Acute and persistent effects of commonly used antibiotics on the gut microbiome and resistome in healthy adults. <i>Cell Reports</i> , 2022, 39, 110649.	2.9	64
7	Persisting uropathogenic <i>Escherichia coli</i> lineages show signatures of niche-specific within-host adaptation mediated by mobile genetic elements. <i>Cell Host and Microbe</i> , 2022, 30, 1034-1047.e6.	5.1	13
8	<i>Clostridioides difficile</i> Infections in Inpatient Pediatric Oncology Patients: A Cohort Study Evaluating Risk Factors and Associated Outcomes. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 302-308.	0.6	12
9	Impact of no-touch ultraviolet light room disinfection systems on <i>Clostridioides difficile</i> infections. <i>American Journal of Infection Control</i> , 2021, 49, 646-648.	1.1	6
10	Epidemiology of Left Ventricular Assist Device Infections: Findings From a Large Nonregistry Cohort. <i>Clinical Infectious Diseases</i> , 2021, 72, 190-197.	2.9	19
11	OUP accepted manuscript. <i>journal of applied laboratory medicine</i> , The, 2021, , .	0.6	0
12	Randomized Controlled Trial of Oral Vancomycin Treatment in <i>Clostridioides difficile</i> -Colonized Patients. <i>MSphere</i> , 2021, 6, .	1.3	20
13	Repeat SARS-CoV-2 testing after recovery. Is a pretransplant PCR necessary?. <i>American Journal of Transplantation</i> , 2021, 21, 3206-3207.	2.6	11
14	The role of chronic suppressive antibiotics therapy in superficial drive line infection relapse of left ventricular assist devices: A retrospective cohort from a tertiary care center. <i>Transplant Infectious Disease</i> , 2021, 23, e13686.	0.7	5
15	Can prediction scores be used to identify patients at risk of <i>Clostridioides difficile</i> infection?. <i>Current Opinion in Gastroenterology</i> , 2021, Publish Ahead of Print, 7-14.	1.0	1
16	Antibiotic stewardship teams and <i>Clostridioides difficile</i> practices in United States hospitals: A national survey in The Joint Commission antibiotic stewardship standard era. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 1-6.	1.0	6
17	How clean is clean enough? An observational pilot study to assess central sterilization processing efficacy with adenosine triphosphate levels. <i>American Journal of Infection Control</i> , 2020, 48, 420-422.	1.1	3
18	Comparing intervention strategies for reducing <i>Clostridioides difficile</i> transmission in acute healthcare settings: an agent-based modeling study. <i>BMC Infectious Diseases</i> , 2020, 20, 799.	1.3	13

#	ARTICLE	IF	CITATIONS
19	Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of <i>Clostridioides</i> (<i>Clostridium</i>) <i>difficile</i> Infection. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa157.	0.4	12
20	Strategies to prevent adverse outcomes following <i>Clostridioides difficile</i> infection in the elderly. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 203-217.	2.0	3
21	Assessment of antibiotic-resistant organism transmission among rooms of hospitalized patients, healthcare personnel, and the hospital environment utilizing surrogate markers and selective bacterial cultures. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 539-546.	1.0	2
22	A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of <i>Clostridium difficile</i> associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2019, 68, 196-203.	2.9	41
23	Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent <i>Clostridioides difficile</i> Infection: A Post Hoc Analysis of MODIFY I/II. <i>Open Forum Infectious Diseases</i> , 2019, 6, .	0.4	8
24	Impact of an electronic hard-stop clinical decision support tool to limit repeat <i>Clostridioides difficile</i> toxin enzyme immunoassay testing on test utilization. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 1423-1426.	1.0	10
25	Performance of laboratory tests for detection for <i>Clostridioides difficile</i> : A multicenter prospective study in Japan. <i>Anaerobe</i> , 2019, 60, 102107.	1.0	7
26	Comparative Genomics of Antibiotic-Resistant Uropathogens Implicates Three Routes for Recurrence of Urinary Tract Infections. <i>MBio</i> , 2019, 10, .	1.8	73
27	Management of <i>Clostridioides</i> (formerly <i>Clostridium</i>) <i>difficile</i> infection (CDI) in solid organ transplant recipients: Guidelines from the American Society of Transplantation Community of Practice. <i>Clinical Transplantation</i> , 2019, 33, e13564.	0.8	35
28	<i>Clostridioides</i> (<i>Clostridium</i>) <i>difficile</i> infection burden in Japan: A multicenter prospective study. <i>Anaerobe</i> , 2019, 60, 102011.	1.0	47
29	Cytomegalovirus Infections of the Stem Cell Transplant Recipient and Hematologic Malignancy Patient. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 485-500.	1.9	21
30	Quantitative Results of a National Intervention to Prevent <i>Clostridioides difficile</i> Infection. <i>Annals of Internal Medicine</i> , 2019, 171, S52.	2.0	6
31	<i>Clostridium difficile</i> infection increases acute and chronic morbidity and mortality. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 65-71.	1.0	35
32	Metabolomic networks connect host-microbiome processes to human <i>Clostridioides difficile</i> infections. <i>Journal of Clinical Investigation</i> , 2019, 129, 3792-3806.	3.9	70
33	A Tiered Approach for Preventing <i>Clostridioides difficile</i> Infection. <i>Annals of Internal Medicine</i> , 2019, 171, S45.	2.0	8
34	Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study. <i>Transplant Infectious Disease</i> , 2018, 20, e12877.	0.7	19
35	Clinical Practice Guidelines for <i>Clostridium difficile</i> Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clinical Infectious Diseases</i> , 2018, 66, e1-e48.	2.9	1,695
36	Epidemiology and outcomes of <i>Clostridium difficile</i> infection in allogeneic hematopoietic cell and lung transplant recipients. <i>Transplant Infectious Disease</i> , 2018, 20, e12855.	0.7	32

#	ARTICLE	IF	CITATIONS
37	<i>Clostridium difficile</i> control measures: current and future methods for prevention. Expert Review of Anti-Infective Therapy, 2018, 16, 121-131.	2.0	15
38	Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660 Microbiota-Based Drug for the Prevention of Recurrent <i>Clostridium difficile</i> Infection. Clinical Infectious Diseases, 2018, 67, 1198-1204.	2.9	96
39	Frequency of Instrument, Environment, and Laboratory Technologist Contamination during Routine Diagnostic Testing of Infectious Specimens. Journal of Clinical Microbiology, 2018, 56, .	1.8	9
40	Clinical Practice Guidelines for <i>Clostridium difficile</i> Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases, 2018, 66, 987-994.	2.9	900
41	Bezlotoxumab for Prevention of Recurrent <i>Clostridium difficile</i> Infection in Patients at Increased Risk for Recurrence. Clinical Infectious Diseases, 2018, 67, 649-656.	2.9	143
42	1950. Prevention of Recurrent <i>Clostridium difficile</i> at Six Months Following Treatment With Microbiota-Based Therapy RBX2660: Durability Results From a Phase 2 Open-Label Study. Open Forum Infectious Diseases, 2018, 5, S562-S563.	0.4	0
43	Impact of Amoxicillin-Clavulanate followed by Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential. MSphere, 2018, 3, .	1.3	17
44	Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials. Open Forum Infectious Diseases, 2018, 5, ofy218.	0.4	7
45	Increasing Age Has Limited Impact on Risk of <i>Clostridium difficile</i> Infection in an Elderly Population. Open Forum Infectious Diseases, 2018, 5, ofy160.	0.4	26
46	<i>Clostridium difficile</i> colonization among patients with clinically significant diarrhea and no identifiable cause of diarrhea. Infection Control and Hospital Epidemiology, 2018, 39, 1330-1333.	1.0	10
47	Reply to Million et al. Clinical Infectious Diseases, 2018, 67, 1799-1800.	2.9	0
48	Current management of Clostridioides (<i>Clostridium</i>) <i>difficile</i> infection in adults: a summary of recommendations from the 2017 IDSA/SHEA clinical practice guideline. Polish Archives of Internal Medicine, 2018, 129, 189-198.	0.3	4
49	Risk for <i>Clostridium difficile</i> Infection After Allogeneic Hematopoietic Cell Transplant Remains Elevated in the Postengraftment Period. Transplantation Direct, 2017, 3, e145.	0.8	22
50	Evaluation of Correlation between Pretest Probability for <i>Clostridium difficile</i> Infection and <i>Clostridium difficile</i> Enzyme Immunoassay Results. Journal of Clinical Microbiology, 2017, 55, 596-605.	1.8	13
51	An Evaluation of the Prevalence of Vancomycin-Resistant <i>Enterococci</i> (VRE) and Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) in Hospital Food. Infection Control and Hospital Epidemiology, 2017, 38, 1373-1375.	1.0	3
52	Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for <i>Clostridium difficile</i> Infection. Clinical Infectious Diseases, 2017, 65, 1218-1221.	2.9	18
53	Pathogenicity Locus, Core Genome, and Accessory Gene Contributions to <i>Clostridium difficile</i> Virulence. MBio, 2017, 8, .	1.8	51
54	Reducing Fluoroquinolone Use Is a Key Step in Controlling the Burden of <i>Clostridium difficile</i> Infection. Gastroenterology, 2017, 153, 606-607.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Assessment of Healthcare Worker Protocol Deviations and Self-Contamination During Personal Protective Equipment Donning and Doffing. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 1077-1083.	1.0	128
56	Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. <i>Transplant Infectious Disease</i> , 2017, 19, e12629.	0.7	75
57	Infections in Hematopoietic Cell Transplant Recipients: Results From the Organ Transplant Infection Project, a Multicenter, Prospective, Cohort Study. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx050.	0.4	89
58	Pitfalls Associated With the Use of Molecular Diagnostic Panels in the Diagnosis of Cryptococcal Meningitis. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx242.	0.4	30
59	Epidemiological and economic burden of <i>Clostridium difficile</i> in the United States: estimates from a modeling approach. <i>BMC Infectious Diseases</i> , 2016, 16, 303.	1.3	131
60	Healthcare Worker Self-Contamination During Standard and Ebola Virus Disease Personal Protective Equipment Doffing. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	5
61	Epidemiology of Initial and Recurrent Episodes of Infection in Left Ventricular Assist Device Recipients. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
62	Effect of an Electronic Hard-Stop Intervention to Prevent Repeat <i>Clostridium difficile</i> Toxin Testing on Test Utilization and Clinical Outcomes. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
63	Impact of Amoxicillin/Clavulanate and Autologous Fecal Microbiota Transplantation (FMT) on the Fecal Microbiome and Resistome. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
64	Quantitative Responses of Taxonomic Composition and Resistance Gene Abundance in the Gut Microbiota to Fecal Microbiota Transplantation. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
65	Lack of Evidence for Toxin Immunoassay-Negative Patients as a Significant Source of <i>Clostridium difficile</i> Transmission at an Academic Medical Center. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
66	Efficacy of Bezlotoxumab in Patients Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of <i>Clostridium difficile</i> Infection (CDI). <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	2
67	Efficacy and Safety of RBX2660 for the Prevention of Recurrent <i>Clostridium difficile</i> Infection: Results. of the PUNCH CD 2 Trial. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	9
68	Antibodies to Toxin B Are Protective Against <i>Clostridium difficile</i> Infection Recurrence. <i>Clinical Infectious Diseases</i> , 2016, 63, 730-734.	2.9	60
69	An Evaluation of Food as a Potential Source for <i>Clostridium difficile</i> Acquisition in Hospitalized Patients. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 1401-1407.	1.0	13
70	Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. <i>Haematologica</i> , 2016, 101, e465-e468.	1.7	54
71	Clearance of Vancomycin-Resistant <i>Enterococcus</i> Concomitant With Administration of a Microbiota-Based Drug Targeted at Recurrent <i>Clostridium difficile</i> Infection. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw133.	0.4	57
72	The burden of <i>clostridium difficile</i> infection: estimates of the incidence of CDI from U.S. Administrative databases. <i>BMC Infectious Diseases</i> , 2016, 16, 177.	1.3	39

#	ARTICLE	IF	CITATIONS
73	Clostridium difficile – Diagnostic and Clinical Challenges. Clinical Chemistry, 2016, 62, 310-314.	1.5	13
74	Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study. Clinical Infectious Diseases, 2016, 62, 596-602.	2.9	140
75	Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors. Biology of Blood and Marrow Transplantation, 2016, 22, 359-370.	2.0	127
76	Identification of Medicare Recipients at Highest Risk for Clostridium difficile Infection in the US by Population Attributable Risk Analysis. PLoS ONE, 2016, 11, e0146822.	1.1	31
77	Randomized Controlled Trial to Determine the Impact of Probiotic Administration on Colonization With Multidrug-Resistant Organisms in Critically Ill Patients. Infection Control and Hospital Epidemiology, 2015, 36, 1451-1454.	1.0	24
78	Clostridium difficile Infection Among Veterans Health Administration Patients. Infection Control and Hospital Epidemiology, 2015, 36, 1038-1045.	1.0	16
79	Clostridium Difficile Infection in the United States: A National Study Assessing Preventive Practices Used and Perceptions of Practice Evidence. Infection Control and Hospital Epidemiology, 2015, 36, 969-971.	1.0	8
80	The Morbidity, Mortality, and Costs Associated with Clostridium difficile Infection. Infectious Disease Clinics of North America, 2015, 29, 123-134.	1.9	148
81	Procedure-specific surgical site infection incidence varies widely within certain National Healthcare Safety Network surgery groups. American Journal of Infection Control, 2015, 43, 617-623.	1.1	41
82	Impact of Clostridium difficile recurrence on hospital readmissions. American Journal of Infection Control, 2015, 43, 318-322.	1.1	49
83	Risk Factors for Acquisition and Loss of Clostridium difficile Colonization in Hospitalized Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 4533-4543.	1.4	49
84	Ceftolozane-Tazobactam Activity against Phylogenetically Diverse Clostridium difficile Strains. Antimicrobial Agents and Chemotherapy, 2015, 59, 7084-7085.	1.4	2
85	Diagnosis of Clostridium difficile Infection. JAMA Internal Medicine, 2015, 175, 1801.	2.6	37
86	1796 Recovery of Clostridium difficile, Vancomycin Resistant Enterococcus and Methicillin Resistant Staphylococcus aureus from the Food of Hospitalized Patients. Open Forum Infectious Diseases, 2014, 1, S62-S62.	0.4	0
87	113 Procedure-specific Surgical Site Infection (SSI) Prevalence Widely Varies within Certain NHSN (National Healthcare Safety Network) Surgery Groups. Open Forum Infectious Diseases, 2014, 1, S8-S9.	0.4	0
88	1657 Who Seeks a Fecal Microbiota Transplant for Recurrent C. difficile Infection?: Patient Profile of the PUNCH CD Study. Open Forum Infectious Diseases, 2014, 1, S443-S443.	0.4	0
89	1028 The Prevalence of Clostridium difficile Infection (CDI) is Highly Correlated with the Prevalence of Surgical Site Infection (SSI). Open Forum Infectious Diseases, 2014, 1, S301-S301.	0.4	0
90	Attributable Inpatient Costs of Recurrent Clostridium difficile Infections. Infection Control and Hospital Epidemiology, 2014, 35, 1400-1407.	1.0	44

#	ARTICLE	IF	CITATIONS
91	Hospital roommates and development of health care-associated Clostridium difficile infection. American Journal of Infection Control, 2014, 42, 1109-1111.	1.1	6
92	Phenotypic and Genotypic Analysis of Clostridium difficile Isolates: a Single-Center Study. Journal of Clinical Microbiology, 2014, 52, 4260-4266.	1.8	35
93	Clostridium difficile infection in solid organ transplant recipients. Current Opinion in Infectious Diseases, 2014, 27, 336-341.	1.3	14
94	Strategies to Prevent Clostridium difficile Infections in Acute Care Hospitals: 2014 Update. Infection Control and Hospital Epidemiology, 2014, 35, 628-645.	1.0	175
95	A Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals: 2014 Updates. American Journal of Infection Control, 2014, 42, 820-828.	1.1	53
96	Incidence and mortality associated with Clostridium difficile infection at a Japanese tertiary care center. Anaerobe, 2014, 25, 5-10.	1.0	48
97	Burden of Clostridium difficile on the Healthcare System. Clinical Infectious Diseases, 2012, 55, S88-S92.	2.9	489
98	Implementing Automated Surveillance for Tracking Clostridium difficile Infection at Multiple Healthcare Facilities. Infection Control and Hospital Epidemiology, 2012, 33, 305-308.	1.0	19
99	Strategies for prevention of Clostridium difficile infection. Journal of Hospital Medicine, 2012, 7, S14-S17.	0.7	18
100	Clostridium difficile infection: The scope of the problem. Journal of Hospital Medicine, 2012, 7, S1-4.	0.7	44
101	Development and Validation of a Clostridium difficile Infection Risk Prediction Model. Infection Control and Hospital Epidemiology, 2011, 32, 360-366.	1.0	89
102	Clostridium difficile in the ICU. Chest, 2011, 140, 1643-1653.	0.4	62
103	The Impact of ICD-9-CM Code Rank Order on the Estimated Prevalence of Clostridium difficile Infections. Clinical Infectious Diseases, 2011, 53, 20-25.	2.9	48
104	Impact of Clinical Symptoms on Interpretation of Diagnostic Assays for Clostridium difficile Infections. Journal of Clinical Microbiology, 2011, 49, 2887-2893.	1.8	168
105	Clostridium difficile-associated disease in allogeneic hematopoietic stem cell transplant recipients: risk associations, protective associations, and outcomes. Clinical Transplantation, 2010, 24, 192-198.	0.8	72
106	Multicenter Study of Surveillance for Hospital-Onset Clostridium difficile Infection by the Use of ICD-9-CM Diagnosis Codes. Infection Control and Hospital Epidemiology, 2010, 31, 262-268.	1.0	63
107	Prevention of Healthcare-Associated Clostridium difficile Infection: What Works?. Infection Control and Hospital Epidemiology, 2010, 31, S38-S41.	1.0	16
108	Multicenter Study of Clostridium difficile Infection Rates from 2000 to 2006. Infection Control and Hospital Epidemiology, 2010, 31, 1030-1037.	1.0	85

#	ARTICLE	IF	CITATIONS
109	Review of Current Literature on the Economic Burden of <i>Clostridium difficile</i> Infection. <i>Infection Control and Hospital Epidemiology</i> , 2009, 30, 57-66.	1.0	167
110	Hospital-Associated <i>Clostridium difficile</i> Infection: Is It Necessary to Track Community-Onset Disease?. <i>Infection Control and Hospital Epidemiology</i> , 2009, 30, 332-337.	1.0	18
111	Multicenter Study of the Impact of Community-Onset <i>Clostridium difficile</i> Infection on Surveillance for <i>C. difficile</i> Infection. <i>Infection Control and Hospital Epidemiology</i> , 2009, 30, 518-525.	1.0	25
112	Reply to Jaber et al.. <i>Infection Control and Hospital Epidemiology</i> , 2008, 29, 189-190.	1.0	1
113	Strategies to Prevent <i>Clostridium difficile</i> Infections in Acute Care Hospitals. <i>Infection Control and Hospital Epidemiology</i> , 2008, 29, S81-S92.	1.0	172
114	Short- and Long-Term Attributable Costs of <i>Clostridium difficile</i> -Associated Disease in Nonsurgical Inpatients. <i>Clinical Infectious Diseases</i> , 2008, 46, 497-504.	2.9	168
115	Reply to Goorhuis et al.. <i>Clinical Infectious Diseases</i> , 2008, 47, 430-431.	2.9	1
116	Attributable Outcomes of Endemic <i>Clostridium difficile</i> -Associated Disease in Nonsurgical Patients. <i>Emerging Infectious Diseases</i> , 2008, 14, 1031-1038.	2.0	148
117	<i>Clostridium difficile</i> infection in solid organ transplant recipients. <i>Current Opinion in Organ Transplantation</i> , 2008, 13, 592-600.	0.8	82
118	A woman from Honduras with a painful forearm and fever. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 78, 697-8.	0.6	0
119	Evaluation of <i>Clostridium difficile</i> -Associated Disease Pressure as a Risk Factor for <i>C. difficile</i> -Associated Disease. <i>Archives of Internal Medicine</i> , 2007, 167, 1092.	4.3	119
120	Prevalence of <i>Clostridium difficile</i> environmental contamination and strain variability in multiple health care facilities. <i>American Journal of Infection Control</i> , 2007, 35, 315-318.	1.1	137
121	Severity of <i>Clostridium difficile</i> -Associated Disease (CDAD) in Allogeneic Stem Cell Transplant Recipients: Evaluation of a CDAD Severity Grading System. <i>Infection Control and Hospital Epidemiology</i> , 2007, 28, 208-211.	1.0	40
122	<i>Clostridium difficile</i> -Associated Disease in a Setting of Endemicity: Identification of Novel Risk Factors. <i>Clinical Infectious Diseases</i> , 2007, 45, 1543-1549.	2.9	241
123	Acute meningoencephalitis caused by adenovirus serotype 26. <i>Journal of NeuroVirology</i> , 2006, 12, 235-240.	1.0	40
124	<i>Clostridium Difficile</i> -Associated Disease in Allogeneic Transplant Patients.. <i>Blood</i> , 2004, 104, 5095-5095.	0.6	0
125	Infections in Oncology Patients. , 0, , 315-324.		0